Please Wait...

Reproducibility of a Semi-automatic Knee Joint Analysis Tool

*Yu HJ, *Zhang Y, *Morges S, *Dawson E, *Galante N, *Belaroussi B, **Hoover KB, *Miller CG.

*BioClinica, Inc., Newtown, PA 18940
**Department of Radiology, VCU Medical Center, Richmond, PA 23219

BACKGROUND: Minimal Joint Space Width (mJSW, defined as the narrowest point of the tibio-femoral joint), and Anatomical Axis Angle (AAA, the angle formed by the lines bisecting the femur and the tibia as they intersect at the center of the tibial spine tips on plain radiographs of the knee can be used to evaluate the severity and progression of knee osteoarthritis  These measurements are therefore useful in determining subject eligibility and safety in clinical trials for osteoarthritis treatment.  To be practical for clinical trials, an efficient, accurate and precise measurement system is required which also features the QC tool for Inter-margin-distance (IMD).
OBJECTIVE: To evaluate a new semi-automated knee joint analysis tool to measure mJSW, AAA and IMD for use in clinical trials.

METHODS: Both mJSW and AAA were automatically calculated with minimal user interactions (Figure 1 and 2), while IMD was measured using a built-in caliper. Both mJSW and AAA were measured on AP knee radiographs from 30 subjects, by two experienced users, to assess inter- and intra-observer reproducibility. The Mean (and SD) value of absolute difference in each measurement was computed. IMD precision was not evaluated in this study. The 30 radiographs were obtained from a previous OA trial and had a range of KL scores from 0 to 4.

RESULTS: Table 1 and 2 show both the intra- and inter-observer intraclass correlation coefficient (ICC) values as well as repeatability coefficients (RCs) for medial mJSW, lateral mJSW, and AAA.

mJSW

The intra-observer reproducibility of mJSW ranged from 0.95 to 0.99 for ICC and 0.36 to 0.64 mm for RC. The inter-observer reproducibility of mJSW ranged from 0.85 to 0.98 for ICC and 0.59 to 1.33 mm for RC.

AAA

The intra-observer ICC of AAA were 0.95 and 0.97 for observer A and B, respectively. The inter-observer ICC of AAA were 0.85 and 0.92 for session 1 and 2, respectively. The RCs ranged from 1.54o to 3.04o.

CONCLUSION: The analysis tool presented here provided good intra- and inter-observer reproducibility.  The constraints aided in the user a rapid identification of location and reproducible landmarks.  This comprehensive semi-automated analysis tool and is suitable for the assessment of knee joints in clinical trials.

SPONSOR: BioClinica Inc.

DICLOSURE STATEMENT: None

ACKNOWLEDGMENT: None

CORRESPONDENCE ADDRESS: colin.miller@bioclinica.com

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

A great resource for Alzheimers's research teams. https://t.co/qhVP6ImwoO
bioclinica (12 hours ago)
RT @bioclinica: #Pharmacovigilance: Get up-to-speed on latest ind. trends & best practices + hear how others R meeting today's most pressin…
bioclinica (13 hours ago)
RT @Xtalks: Trends in #Pharmacovigilance – Market Research and Future Impact This webinar will discuss an overview of key findings within r…
bioclinica (13 hours ago)
RT @IntClinTrials: Patient loss and can reduced by introducing new methods during the follow-up period. Martin Collyer at @bioclinica tells…
bioclinica (13 hours ago)
@bioclinica experts talk candidly about #Alzheimer's research & where improvements can be made. Joyce Suhy, Marieke… https://t.co/u1Wmu41jRr
bioclinica (13 hours ago)
RT @ACROhealth: @MaryWolleyRA Mary Woolley @ResearchAmerica: 80% have heard of #clinicaltrials. 75% think trial participation is as importa…
bioclinica (1 week ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen